Replies to post #226179 on Biotech Values

[DewDiligence]

LUN.CO—FDA approves Vyepti for migraine prevention—dosed intravenously every 3 months:

https://www.businesswire.com/news/home/20200221005507/en/FDA-Approves-Lundbeck%E2%80%99s-VYEPTI%E2%84%A2-eptinezumab-jjmr-%E2%80%93-Intravenous

Vyepti is a mAb that binds to the CRGP ligand. Lundbeck owns Vyepti as a consequence of the ALDR buyout in Sep 2019 (https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151154641 ).